Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence.

Journal: Expert opinion on drug delivery
Published Date:

Abstract

INTRODUCTION: Interest in nanomedicines has surged in recent years due to the critical role they have played in the COVID-19 pandemic. Nanoformulations can turn promising therapeutic cargo into viable products through improvements in drug safety and efficacy profiles. However, the developmental pathway for such formulations is non-trivial and largely reliant on trial-and-error. Beyond the costly demands on time and resources, this traditional approach may stunt innovation. The emergence of automation, artificial intelligence (AI) and machine learning (ML) tools, which are currently underutilized in pharmaceutical formulation development, offers a promising direction for an improved path in the design of nanomedicines.

Authors

  • Jonathan Zaslavsky
    Leslie Dan Faculty of Pharmacy, University of Toronto, M5S 3M2, Toronto, ON, Canada.
  • Pauric Bannigan
  • Christine Allen